We can’t show the full text here under this license. Use the link below to read it at the source.
Impact of glucagon-like peptide-1 receptor agonists on colonoscopy outcomes: a systematic review and meta-analysis
How Diabetes Drugs Affect Results of Colonoscopy Exams: A Review and Analysis
AI simplified
Abstract
GLP-1 receptor agonist use is associated with a 1.55 times higher risk of before colonoscopy.
- A systematic review and meta-analysis included 12 studies with 123,858 patients, of which 57,699 were using GLP-1 receptor agonists.
- Adjusted analyses indicated that GLP-1 receptor agonist users had an increased risk of inadequate bowel preparation, with an odds ratio of 2.35.
- Users of GLP-1 receptor agonists had significantly lower scores, with a mean difference of -0.68.
- No significant association was found between GLP-1 receptor agonist use and the need for repeat colonoscopies.
AI simplified
Key numbers
1.55
Increase in Risk
Odds ratio for among GLP-1 RA users vs. non-users.
-0.68
Mean Score Decrease
Mean difference in scores between GLP-1 RA users and non-users.
1.5
Repeat Colonoscopy Odds Ratio
Odds ratio for repeat colonoscopy in GLP-1 RA users vs. non-users.